INCYTE CORP
Action · US45337C1027 · INCY · 896133 (XNAS)
68,77 USD
06.06.2025 20:00
Cours actuels de INCYTE CORP
Bourse | Ticker | Devise | Dernier échange | Cours | Variation journalière |
---|---|---|---|---|---|
![]() NASDAQ |
INCY
|
USD
|
06.06.2025 20:00
|
68,77 USD
| 67,24 USD
+2,28 %
|
![]() London |
0J9P.L
|
USD
|
06.06.2025 15:05
|
67,97 USD
| 67,24 USD
+1,09 %
|
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
0,00 % | 5,70 % | 15,37 % | -1,88 % | -9,42 % | 16,44 % | -26,46 % |
Profil de l'entreprise pour INCYTE CORP Action
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Fonds investis
Les fonds suivants ont investi dans : INCYTE CORP investi :
Fonds | Vol. en millions 562,22 | Part (%) 1,32 % |
Fonds | Vol. en millions 659,98 | Part (%) 0,18 % |
Fonds | Vol. en millions 3,86 | Part (%) 0,14 % |
Fonds | Vol. en millions 147,77 | Part (%) 0,14 % |
Fonds | Vol. en millions 214,38 | Part (%) 0,12 % |
Données de l'entreprise
Nom INCYTE CORP
Société Incyte Corporation
Symbole INCY
Site web
https://www.incyte.com
Marché d'origine
NASDAQ

WKN 896133
ISIN US45337C1027
Type de titre Action
Secteur Healthcare
Industrie Medical - Pharmaceuticals
PDG Mr. Herve Hoppenot
Capitalisation boursière 11 Mrd.
Pays États-Unis d'Amérique
Devise USD
Employés 2,6 T
Adresse 1801 Augustine Cut-Off, 19803 Wilmington
Date d'introduction en bourse 2018-01-29
Fractionnements d'actions
Date | Fractionnement |
---|---|
01.09.2000 | 2:1 |
10.11.1997 | 2:1 |
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | ICY.F |
London | 0J9P.L |
NASDAQ | INCY |
Autres actions
Les investisseurs qui détiennent INCYTE CORP ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.